Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Dec 27, 2020 3:27pm
243 Views
Post# 32185655

RE:I'm fairly. Sure more dilution is on the way

RE:I'm fairly. Sure more dilution is on the way
YukonJezza wrote:
and if the reverse split was just a tool to do more raises than this will drop fast.


More dilution will eventually happen - but - I storngly doubt it happens at this price.

The reverse split is just a tool that needs to be deployed and I suggest the winning way is as follows ...
1.  Move to TSX from Venture.
2.  Split.
3.  Drive share price up ... this is where we're at over the next couple months - offering news on the R&D side and on the business development side.
4.  Go to US exchange (likely as we approach P3 but only after sufficient news to drive excitement.  Raising money need not happen at this point but a higher share price is definately required before raising money.
5.  Raise money (if/when needed) - in conjunction with expectations of cash agreements for partnering.  Some potential partnering may be in the works but ATE need not act on any partnering if better deals may be had on corporate and development news.  Hoping this is where we are in control.

---------------

Anything short of this order could be a problem - we've still got lots of time.  That's why I'm hoping an experienced Board has already figured all of this out ... in conjunction with ATE delivering on strategic initiatives.

---------------

Here's to a prosperous New Year !!!! Cheers !!!
<< Previous
Bullboard Posts
Next >>